Explore the cutting-edge advancements in understanding the pancreatic cancer environment, from innovative patient-derived models to the precision of single-cell omics, and how these breakthroughs are revolutionizing our approach to combating this challenging disease.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Pancreatic cancer environment: from patient-derived models to single-cell omics.
Gu et al., Mol Omics 2024
<!– DOI: 10.1039/d3mo00250k //–>
https://doi.org/10.1039/d3mo00250k
This review highlights the significance of patient-derived models (PDMs) such as patient-derived xenografts (PDXs), patient-derived organoids (PDOs), and patient-derived explants (PDEs) in studying pancreatic cancer (PC), a cancer known for its poor prognosis and high heterogeneity. The focus is on how these models offer a more accurate representation of tumor heterogeneity and complexity, surpassing traditional cell line-derived models. The utilization of PDMs is crucial for understanding the intricate intercellular communication within tumors, assessing drug responsiveness, uncovering mechanisms of tumor growth, accelerating drug discovery, and facilitating personalized medicine approaches. Furthermore, the review delves into the application of single-cell analyses of these models, aiming to provide a deeper understanding of intercellular communication among tumor cells, mechanisms of drug response, and individual patient sensitivities. This comprehensive summary underscores the importance of PDMs in advancing our understanding of pancreatic cancer progression and treatment, contributing significantly to the current literature on cancer research.